Organon & Co. $OGN Shares Acquired by Cantor Fitzgerald Investment Advisors L.P.

Cantor Fitzgerald Investment Advisors L.P. increased its position in Organon & Co. (NYSE:OGN) by 50.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 119,363 shares of the company’s stock after buying an additional 40,180 shares during the period. Cantor Fitzgerald Investment Advisors L.P.’s holdings in Organon & Co. were worth $1,155,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Hanson & Doremus Investment Management acquired a new position in shares of Organon & Co. in the second quarter valued at approximately $26,000. Sterneck Capital Management LLC acquired a new position in shares of Organon & Co. in the second quarter valued at approximately $456,000. State of Alaska Department of Revenue raised its position in shares of Organon & Co. by 110.7% in the second quarter. State of Alaska Department of Revenue now owns 300,714 shares of the company’s stock valued at $2,910,000 after buying an additional 158,014 shares during the last quarter. Perigon Wealth Management LLC acquired a new position in shares of Organon & Co. in the second quarter valued at approximately $126,000. Finally, Wealth Effects LLC raised its position in shares of Organon & Co. by 9.7% in the second quarter. Wealth Effects LLC now owns 64,840 shares of the company’s stock valued at $628,000 after buying an additional 5,736 shares during the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Stock Performance

NYSE:OGN opened at $11.00 on Thursday. Organon & Co. has a 1-year low of $8.01 and a 1-year high of $19.05. The company has a debt-to-equity ratio of 11.98, a current ratio of 1.65 and a quick ratio of 1.13. The firm has a 50 day simple moving average of $9.82 and a 200-day simple moving average of $10.47. The firm has a market cap of $2.86 billion, a PE ratio of 4.09, a P/E/G ratio of 0.97 and a beta of 0.63.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.00 earnings per share for the quarter, topping analysts’ consensus estimates of $0.94 by $0.06. The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. Organon & Co.’s revenue was down .8% on a year-over-year basis. During the same quarter last year, the firm posted $1.12 earnings per share. Organon & Co. has set its FY 2025 guidance at EPS. On average, equities analysts expect that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, September 11th. Shareholders of record on Friday, August 15th were paid a dividend of $0.02 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $0.08 dividend on an annualized basis and a yield of 0.7%. Organon & Co.’s dividend payout ratio (DPR) is currently 2.97%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.